|Study Type:||Phase I/IIa|
|Stage:||Follow up complete|
|Study Start Date:||NA|
|Study Made Public:||NA|
A Phase 1/2a partially double-blinded, randomized clinical trial to characterize the safety and immunogenicity of clade C ALVAC-HIV (vCP2438) and bivalent subtype C gp120 alone, with MF59 adjuvant, and with alum adjuvant in healthy, HIV-uninfected adult participants
HVTN 107 is a Phase I/IIa clinical trial to evaluate the safety and immunogenicity of ALVAC-HIV (vCP2438) and bivalent subtype C gp120 (alone or with MF59 or alum).
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.